Effects of parathyroidectomy on lead mobilization from bone in patients with primary hyperparathyroidism

Bone

Volumn 35, Issue 4, 2004, Pages 942-947

  Osterode, W ^a   Winker, R ^a   Bieglmayer, C ^b   Vierhapper, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Klinisches Inst F Med C   (Austria)

Author keywords

Cross linked telopeptide; Hyperparathyroidism; Lead metabolism; Osteocalcin; Parathyroid hormone

Indexed keywords

LEAD; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PYRIDINOLINE; TELOPEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BONE REMODELING; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; FEMALE; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PARATHYROIDECTOMY; URINALYSIS;

BONE AND BONES; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM; LEAD; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHATES;

EID: 5344269439     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.05.022     Document Type: Article

References (36)

1. von Storch H., Costa-Cabral M., Hagner C., Feser F., Pacyna J., Pacyna E., et al. Four decades of gasoline lead emissions and control policies in Europe: a retrospective assessment. Sci. Total Environ. 311(1-3):2003 (Jul 20);151-176
2. Pirkle J.L., Brody D.J., Gunter E.W., Kramer R.A., Paschal D.C., Flegal K.M., et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA. 272(4):1994;284-291
3. Hu H., Aro A., Payton M., Korrick S., Sparrow D., Weiss S.T., et al. The relationship of bone and blood lead to hypertension. The Normative Aging Study. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA. 275(15):1996;1171-1176
4. Payton M., Riggs K.M., Spiro A. III, Weiss S.T., Hu H. Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol. Teratol. 20(1):1998;19-27
5. Barth A., Schaffer A.W., Osterode W., Winker R., Konnaris C., Valic E., et al. Reduced cognitive abilities in lead-exposed men. Int. Arch. Occup. Environ. Health. 75(6):2002;394-398
6. Barry P.S. A comparison of concentrations of lead in human tissues. Br. J. Ind. Med. 32:1975;119-139
7. Rabinowitz M.B. Toxicokinetics of bone lead. Environ. Health Perspect. 91:1991;33-37
8. Wittmers L.E. Jr., Aufderheide A.C., Wallgren J., Rapp G. Jr., Alich A. Lead in bone. IV. Distribution of lead in the human skeleton. Arch. Environ. Health. 43:1988;381-391
9. Nilsson U., Attewell R., Christoffersson J.O., Schutz A., Ahlgren L., Skerfving S., et al. Kinetics of lead in bone and blood after end of occupational exposure. Pharmacol. Toxicol. 68:1991;477-484
10. Berlin K., Gerhardsson L., Borjesson J., Lindh E., Lundstrom N., Schutz A., et al. Lead intoxication caused by skeletal disease. Scand. J. Work Environ. Health. 21:1995;296-300
11. Goldman R.H., White R., Kales S.N., Hu H. Lead poisoning from mobilization of bone stores during thyrotoxicosis. Am. J. Ind. Med. 25:1994;417-424
12. Osterode W., Reining G., Manner G., Jager J., Vierhapper H. Increased lead excretion correlates with desoxypyridinoline crosslinks in hyperthyroid patients. Thyroid. 10:2000;161-164
13. Tsaih S.W., Korrick S., Schwartz J., Lee M.L., Amarasiriwardena C., Aro A., et al. Influence of bone resorption on the mobilization of lead from bone among middle-aged and elderly men: the Normative Aging Study. Environ. Health Perspect. 109(10):2001;995-999
14. Siddiqi A., Burrin J.M., Noonan K., James I., Wood D.F., Price C.P., et al. A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. J. Clin. Endocrinol. Metab. 82(3):1997;753-759
15. Marx S.J. Hyperparathyroid and hypoparathyroid disorders. N. Engl. J. Med. 343:2000;1863-1875
16. Ishizuya T., Yokose S., Hori M., Noda T., Suda T., Yoshiki S., et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99:1997;2961-2970
17. Schiller P.C., D'Ippolito G., Roos B.A., Howard G.A. Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. J. Bone Miner. Res. 14:1999;1504-1512
18. Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Heickendorff L., et al. Primary hyperparathyroidism: effect of parathyroid-ectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone. 25(5):1999;589-595
19. Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Charles P., et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 21:1997;93-99
20. Silverberg S.J., Gartenberg F., Jacobs T.P., Shane E., Siris E., Staron R.B., et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80:1995;729-734
21. Long G.J., Rosen J.F., Pounds J.G. Cellular lead toxicity and metabolism in primary and clonal osteoblastic bone cells. Toxicol. Appl. Pharmacol. 102:1990;346-361
22. Long G.J., Rosen J.F., Pounds J.G. Lead impairs the production of osteocalcin by rat osteosarcoma (ROS 17/2.8) cells. Toxicol. Appl. Pharmacol. 106:1990;270-277
23. Pounds J.G., Rosen J.F. Cellular metabolism of lead: a kinetic analysis in cultured osteoclastic bone cells. Toxicol. Appl. Pharmacol. 83:1986;531-545
24. Osterloh J.D., Clark O.H. Effects of hyperparathyroidism on blood lead concentrations in man. Environ. Res. 62:1993;1-6
25. Prager G., Czerny C., Kurtaran A., Passler C., Scheuba C., Bieglmayer C., et al. Minimally invasive open parathyroidectomy in an endemic goiter area: a prospective study. Arch. Surg. 136:2001;810-816
26. Brito J.A., McNeill F.E., Stronach I., Webber C.E., Wells S., Richard N., et al. Longitudinal changes in bone lead concentration: implications for modelling of human bone lead metabolism. J. Environ. Monit. 3(4):2001 (Aug);343-351
27. Osterode W., Zettinig G., Potzi C., Manner G. Increased lead excretion in hypothyroid patients after levothyroxine medication. J. Toxicol. Environ. Health, A. 65:2002;649-654
28. Pagani F., Bonetti G., Stefini F., Panteghini M. Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum. Clin. Chem. Lab. Med. 38:2000;1111-1113
29. Garnero P., Borel O., Del mas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin. Chem. 47:2001;694-702
30. Pounds J.G., Long G.J., Rosen J.F. Cellular and molecular toxicity of lead in bone. Environ. Health Perspect. 91:1991;17-32
31. Rosen J.F., Pounds J.G. Quantitative interactions between Pb2+ and Ca2+ homeostasis in cultured osteoclastic bone cells. Toxicol. Appl. Pharmacol. 98:1989;530-543
32. Mouw D.R., Wagner J.G., Kalitis K., Vander A.J., Mayor G.H. The effect of parathyroid hormone on the renal accumulation of lead. Environ. Res. 15:1978;20-27
33. Flanagan J.L., Friedman P.A. Parathyroid hormone-stimulated cadmium accumulation in Madin-Darby canine kidney cells. Toxicol. Appl. Pharmacol. 109:1991;241-250
34. Friedman P.A., Gesek F.A. Cadmium uptake by kidney distal convoluted tubule cells. Toxicol. Appl. Pharmacol. 128:1994;257-263
35. Tomsig J.L., Suszkiw J.B. Permeation of Pb2+ through calcium channels: fura-2 measurements of voltage- and dihydropyridine-sensitive Pb2+ entry in isolated bovine chromaffin cells. Biochim. Biophys. Acta. 1069:1991;197-200
36. Fowler B.A., DuVal G. Effects of lead on the kidney: roles of high-affinity lead-binding proteins. Environ. Health Perspect. 91:1991;77-80